Results 11 to 20 of about 195,924 (307)

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic [PDF]

, 2020
The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or ...
Martí, Covadonga, Sánchez-Méndez, José I.   +1 more
core   +1 more source

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression

Frontiers in Oncology, 2022
IntroductionNeoadjuvant trastuzumab plus chemotherapy may affect programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer.
Mao Shang, Mao Shang, Yajing Chi, Jianbo Zhang, Jin Chang, Hui Yang, Sha Yin, Qiaorui Tan, Xiaochu Man, Huihui Li   +9 more
doaj   +1 more source

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

Frontiers in Oncology, 2022
Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated.
Chaoyuan Liu, Min Lu, Yang Yang, Xiang Wang, Fang Ma, Xianling Liu   +5 more
doaj   +1 more source

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

Frontiers in Immunology, 2022
BackgroundAn open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operable ...
Linping Gu, Xue Wang, Yile Sun, Yunhua Xu, Xiaomin Niu, Ruiying Zhao, Yaxian Yao, Hong Jian, Yuchen Han, Jinwang Wei, Zhiwei Chen, Shun Lu   +11 more
doaj   +1 more source

Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) [PDF]

, 2011
Every 2 years, the International Consensus Conference on the Treatment of Primary Breast Cancer takes place in St. Gallen. Given that the concept of the St.
Beckmann, Matthias W., Blohmer, Jens-Uwe, Costa, Serban-Dan, Diedrich, Klaus, Diel, Ingo, Eiermann, Wolfgang, Friese, Klaus, Gerber, Bernd, Harbeck, Nadia, Hilfrich, Jörn, Jackisch, Christian, Janni, Wolfgang, Jonat, Walter, Jänicke, Fritz, Kaufmann, Manfred, Kiechle, Marion, Kreienberg, Rolf, Köhler, Uwe, Maass, Nicolai, Marschner, Norbert, Minckwitz, Gunter von, Möbus, Volker, Nitz, Ulrike, Scharl, Anton, Schneeweiss, Andreas, Thomssen, Christoph, Untch, Michael, Wallwiener, Diethelm   +27 more
core   +1 more source

Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2020
Objective: Neoadjuvant chemotherapy has increased the survival benefit of non-small cell lung cancer (NSCLC) patients. The effects of different neoadjuvant therapies are still controversial. We carried out the study to evaluate the efficacy and safety of
Yijiu Ren, Hai Tang, Jie Zhang, Yunlang She, Xiaoting Sun, Dong Xie, Chang Chen   +6 more
doaj   +1 more source

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer

Frontiers in Immunology, 2023
ObjectivesRecent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response.
Jie Shen, Linping Gu, Yuwen Qi, Yaxian Yao, Shun Lu, Zhiwei Chen   +5 more
doaj   +1 more source

Management of inoperable endometrial cancer [PDF]

Obstetrics & Gynecology Science, 2022
Some endometrial cancer (EMC) patients are not good candidates for primary surgery. The three major types of treatment for inoperable EMC are radiation therapy, chemotherapy, or their combination as neoadjuvant treatment before surgery. Radiation therapy
Supakorn Pitakkarnkul, Saranya Chanpanitkitchot, Siriwan Tangjitgamol   +2 more
doaj   +1 more source

The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients [PDF]

, 2018
Background: Preoperative chemoradiotherapy (CRT) followed by surgery is the standard care for locally advanced rectal cancer, but tumour response to CRT and disease outcome are variable.
A Celeghin, A Habr-Gama, AL Appelt, Alessandro Perin, AM Mandard, Angela Buonadonna, Anita De Rossi, Antonino De Paoli, C Alix-Panabières, C Belluco, Caterina Boso, Claudio Belluco, D Beddy, D Hanahan, D Lin, D Tural, E Rampazzo, E Rampazzo, E Rampazzo, EH Blackburn, Elisa Palazzari, Enrica Rampazzo, Francesca Bergamo, G Saretzki, G Spolverato, Giovanna Spiro, I Gingras, J Buijsen, J Maláska, JA March-Villalba, JF Bosset, JM Lewis, JP Gerard, K Bujko, K Kojima, L Moureau-Zabotto, L Terrin, L Terrin, LA Torre, M Maas, M Spornraft, MB Amin, MS Roh, N Miura, N Tani, P Boscolo-Rizzo, Paola Del Bianco, R Bertorelle, R Bertorelle, R Sauer, R Siegel, RK Deblakshmi, Roberta Bertorelle, S Giunco, S Pucciarelli, S Pucciarelli, Salvatore Pucciarelli, Sara Leonardi, SB Edge, SH Lim, SM Lledó, T El-Hefnawy, Y Kang   +62 more
core   +1 more source

Ifosfamide with regional hyperthermia in soft-tissue sarcomas [PDF]

, 2003
For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival.
Issels, Rolf-Dieter, Schlemmer, M., Wendtner, Clemens-Martin   +2 more
core   +1 more source